Study on development of new bactericidal-biocompatible material for conserving infected pulp.

本研究旨在开发最有效的新型杀菌-生物相容性材料来保存感染的牙髓组织。得到了以下结果：1。环丙沙星、甲硝唑和头孢克洛混合使用对感染牙髓组织中的所有细菌均有完全的杀灭效果。通过对厌氧细菌苯丙氨酸和亮氨酸代谢的研究，揭示了甲硝唑的抗菌机制。在成年猴的组织病理学研究中，α -磷酸三钙（α - tcp）作为直接封盖材料表现出良好的生物相容性。组织病理学研究表明，含有混合抗菌药物的α - tcp有效地消毒了被细菌污染的成年猴牙髓病变，而不破坏任何完好的牙髓组织，并在暴露的牙髓表面形成坚硬的组织屏障。含有混合抗菌药物的α - tcp对人类龋齿病变的体外和原位完全消毒研究。在志愿者的体内研究中，人工暴露的牙髓组织被硬组织屏障所转化，而不破坏任何完好的牙髓组织，当含有混合抗菌药物的α - tcp应用于暴露的牙髓组织。在志愿者患者的临床研究中，几乎所有感染牙髓的病例，特别是年轻的病例，通过在α - tcp中加入混合抗菌药物，用硬组织屏障覆盖时间，而没有进行任何牙髓切除或切髓手术。这项工作目前正在进行中。

This study was projected for developing the most effective new bactericidal-biocompatible material to conserve the infected pulp tissue.Following results were obtained :1. A mixture of Ciprofloxacin, Metronidazole and Cefaclor showed the complete bactericidal efficacy against all of the bacteria in the infected pulp tissue.2. The antibacterial mechanism of metronidazole was revealed the investigation of the metabolism of phenylalanine and leucine of anaerobic bacteria.3. alpha-tricalcium phosphate (alpha-TCP) showed the superior biocompatibility as the direct capping material on the histopathological study using adult monkeys.4. The histopathological study showed that alpha-TCP containing mixed antibacterial drugs effectively disinfected the bacterially contaminated pulpal lesions of adult monkeys without destroying any of the sound pulp tissue and formed the hard tissue barrier covering the exposed pulpal surface.5. alpha-TCP containing mixed antibacterial drugs completely disinfected human caries lesions in vitro and in situ studies.6. In the in vivo study of the volunteer peoples, artificially exposed pulp tissue was convered by the hard tissue barrier formation without destroying any of the sound pulp tissue, when alpha-TCP containing mixed antibacterial drugs was applied on the exposed pulp tissue.7. In the clinical study of the volunteer patients, almost cases of the infected pulp, especially young, has been kept without any of the pulpectomy or pulpotomy by the application of the mixed antibacterial drugs added to alpha-TCP and covered with time by the hard tissue barrier.8. This work is now in progress.